Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study-Reference-Cited by-同舟云学术

Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study

Published:2024-03-26 Issue:5 Volume:69 Page:1785-1792
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Carvalhas Gabrielli Anna Maria,Ferretti Francesca,Monico Camilla Maria,Tombetti Enrico,Maconi Giovanni,Romeo Samanta,Piazza O Sed Nicole,Caprioli Flavio,Mazzola Anna Maria,Alicante Saverio,Bertè Roberto,Lolli Elisabetta,Scribano Maria Lia,Buscarini Elisabetta,Ricci Chiara,Carmagnola Stefania,Ardizzone Sandro,Cannatelli Rosanna

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10620-024-08394-w.pdf

Reference25 articles.

1. Raine T, Bonovas S, Burisch J et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohn’s Colitis. 2022;16:2–17.

2. Brostrom O. Prognosis in ulcerative colitis. Med Clin North Am. 1990;74:201–218.

3. Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505.

4. Ferretti F, Cannatelli R, Monico MC et al. An update on current pharmacotherapeutic options for the treatment of ulcerative colitis. J Clin Med. 2022;11:2302.

5. Amiot A, Serrero M, Peyrin-Biroulet L et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Therapeutics. 2017;46:310–321.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tofacitinib in Ulcerative Colitis – Second-Line Therapy, First-Rate Results;Digestive Diseases and Sciences;2024-08-22